Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell cocktail aims to prevent transplant complications in kids with leukemia

NCT ID NCT07366801

Recruiting now Disease control Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new method to prevent graft-versus-host disease (GVHD) in children and young adults with high-risk blood cancers who need a stem cell transplant from a half-matched donor. The approach combines specially enriched donor immune cells with a stem cell graft that has most T cells removed, along with reduced use of immune-suppressing drugs. The goal is to lower the risk of severe GVHD while keeping the immune system strong enough to fight infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Donor lymphocytes enriched with regulatory T cells, combined with a stem cell graft that has had most T cells removed

What this could lead to

If successful, this approach could reduce the risk of severe graft-versus-host disease while preserving the immune system's ability to fight infections after a stem cell transplant.

What could go wrong

This is an early pilot study with only 64 participants, so results may not apply to all patients. There is still a risk of graft-versus-host disease or serious infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, RELAPSED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Recurrence graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA, HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA, RELAPSE ACUTE MYELOID LEUKEMIA, HIGH RISK ACUTE MYELOID LEUKEMIA, RELAPSED

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198

    RECRUITING

    Moscow, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••